Botulinum toxin type A in the treatment of Myofascial Pain Syndrome: A Systematic Review
2021; Medical Association of São Paulo; Linguagem: Inglês
10.5327/1516-3180.263
ISSN1806-9460
AutoresGabriel Cerqueira Santos, Caio de Almeida Lellis, Bruno Coelho Duarte Oliveira, Letícia Romeira Belchior, Caíque Seabra Garcia de Menezes Figueiredo, Ledismar José da Silva,
Tópico(s)Linguistics and Language Studies
ResumoIntroduction: Myofascial pain syndrome (MPS) is a regional painful condition characterized by the presence of trigger points in the affected muscles, and botulinum toxin type A (BoNT-A) is a possible therapeutic option. Objectives: To evaluate the safety and efficacy of botulinum toxin in the management of MSD. Design and setting: A systematic review conducted at the Pontifical Catholic University of Goiás. Methodology: A systematic review was conducted in the PubMed, IBECS and VHL databases: “(Myofascial Pain Syndromes OR Myofascial Trigger Point Pain) AND Botulinum toxin”. Randomized studies, clinical trials and case reports published in the last 10 years were selected. Results: Two randomized trials concluded that application of BoNT-A, regard less of the application site, did not show significant improvement in pain intensity compared to the control group. Also, another multicenter, random ized trial reported that application of ToNB-A to the masseter muscles did not result in improvement of SDM within three months of application. Finally, a clinical trial reported improvement in visual numeric scores of myofascial pain in the scapular girdle in subjects who received a second dose (P = 0.019). Conclusion: BoNT-A was not effective in improving SDM at any site of ap plication and in any dosage studied, except in a single study, therefore insuf ficient to state whether subsequent doses have better results.
Referência(s)